Vascepa (icosapent ethyl), licensed from Amarin, is a highly concentrated EPA omega-3 product. Vascepa is prescribed as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Eddingpharm entered into partnership with Cardiome Pharma to bring Brinavess (vernakalant) to China. Brinavess is an intravenous antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Iron isomaltoside is an IV iron compound by complexing ferric hydrox-ide with isomaltoside 1000, a low molecular weight oligosaccharide (= isomalto-oligo-saccharide) with a mean molecular weight of 1000 Daltons in a strong matrix formulation. In Europe, iron isomaltoside is approved for treatment of pa-tients with iron deficiency in whom oral iron administration is unsatisfactory or impossible or where there is a clinical need to deliver iron rapidly. Iron isomaltoside 1000 can rapidly improve the Hemoglobin level and iron deficiency status, increase iron storage and utilization. Iron isomaltoside also has a very good toxicity profile due to a gradual release of iron. The complex stability and molecular weight makes it suitable for IV administration and the high stability and thus low risk of free iron related toxicity allow rapid infusion of high iron doses.
Zolpmist (zolpidem tartrate) Oral Spary, a gamma-aminobutyric acid(GABA) A agonist, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Bioequivalence of Zolpimist and zolpidem tablet can be clearly demonstrated. The time to detectable levels of zolpimed after Zolpimist occurs significantly earlier post dose than zolpidem tablet.